If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 18
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer,
Colorectal,
Gynecologic Cancers,
Esophagus,
Other Urologic,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Esophagus,
Skin Cancers,
Stomach,
Prostate and Urologic Cancers,
Pancreas/Liver,
Breast Cancers,
Other Gastrointestinal,
Sarcoma,
Gastrointestinal Cancers,
Lung,
Thoracic Cancers
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive fo
Objective
A Phase1 Study of NT-112 in Patients with Advanced Solid Tumors Positive for KRAS G12D Mutation
Protocol No
NEOGENE-NT-112-301
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Extensive-Stage
Objective
A Phase 1b 2 Study of I-DXd, ADC, in Combination in Patients with ES-SCLC
Protocol No
DAIICHI-SANKYO-DS7300-189
Categories
A First-in-Human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients with Locally Advanced Un-Resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Objective
Safety, PK and efficacy of QXL138AM in patients with solid tumors and multiple myeloma
Protocol No
NAMMI-QXL138AM-001
PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer
Objective
A Phase II randomized study evaluating Durvalumab with or without personalized treatment for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Protocol No
SWOG-S2409-PRISM
Categories
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of
ABBV-706 Versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Objective
A Phase 3 Study to Evaluate ABBV-706 vs standard of care in patient with Relapsed/Refractory Small Cell Lung Cancer
Protocol No
ABBVIE-M23-384
Categories
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology or Other Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Objective
A Dose-Escalation Study of XL092 in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Protocol No
EXELIXIS-XL092-002
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Objective
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203